Printer Friendly

J. MILLER ASSUMES ADDITIONAL POST AS CHAIRMAN, PRESIDENT AND CEO OF BRUNSWICK BIOMEDICAL

 ROCKVILLE, Md., Nov. 19 /PRNewswire/ -- Survival Technology, Inc. (STI) (NASDAQ-NMS: STIQ) today announced that James H. Miller, president and chief executive officer of STI, has assumed the additional post of chairman and chief executive officer of Brunswick Biomedical Corp. (NYSE: BC). Miller is continuing in his current position with STI and will also remain a board member of STI.
 STI and Brunswick Biomedical expect to strengthen their strategic alliances in the coming years. Brunswick Biomedical purchased STI's Emergency Care Products Division in 1990 and currently manufactures the Cardiobeeper(R) product line for STI. Discussions are underway for further collaborative efforts related to STI's Medical Devices Group.
 "We are extremely grateful for Jim Miller's achievements during the past four years and are pleased that his association with STI will continue," said Robert Herzstein, chairman of STI. "The company is now well positioned in its principal product markets to build on this success."
 Since Miller's arrival, annual sales have nearly doubled from $16.6 million in fiscal 1989 to $30.1 million in fiscal 1993 ended July 31. During the same period, annual pre-tax earnings increased to $3.5 million from a loss of $1.4 million. The company has generated consistent profi?ty the past three fiscal years after having registered consecutive annual losses since 1983.
 "The key to STI's success lies in the accelerated focus on the commercial potential of its exclusive auto-injector technology, which holds great promise as a result of downward pressure on health care costs, the increased development of biotechnology products and drug therapies that must be injected and a corresponding emphasis on self- administration of these products by the patient," Miller said. "We have now developed a family of auto-injector drug delivery systems to meet the expanding needs of biotechnology and pharmaceutical companies, and a growing number of agreements have been reached for the development and supply of new products."
 "A great number of people deserve credit for their roles in the transformation of STI from its traditional orientation as a defense contractor to its position today as a significant force in the development of new medical products," he said. "The past four years have been some of the most rewarding in my career, and I now look forward to applying this experience and insight to the development and growth of Brunswick Biomedical."
 Miller has received a significant equity position in Brunswick, a Boston-based biomedical company that develops, produces and markets cardiac monitoring systems, transesophageal devices and emergency care products. Prior to joining STI, he was executive vice president of Beecham Laboratories, which merged with SmithKline to form SmithKline Beecham.
 STI is a technology-based health care company that designs, develops and produces automatic injectors, prefilled syringes and medical electronics, with a major focus on safe and convenient participation by the patient in injection therapy. The company also supplies customized drug delivery system design, pharmaceutical research and development and GMP-approved sterile product manufacturing to pharmaceutical and biotechnology companies.
 -0- 11/19/93
 /CONTACT: Jeffrey W. Church, 301-216-2907, or Sam Huff, 708-382-7404, both for Survival Technology/
 (STIQ BC)


CO: Survival Technology, Inc.; Brunswick Biomedical Corp. ST: Maryland IN: MTC SU: PER

DT-DC -- DC020 -- 4473 11/19/93 16:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 19, 1993
Words:532
Previous Article:AIM 85 DECLARES MONTHLY DISTRIBUTION FOR NOVEMBER OF 21 CENTS PER UNIT
Next Article:CRITEF-III PARTNERSHIP DECLARES MONTHLY DISTRIBUTION FOR NOVEMBER OF 13.68 CENTS PER BAC
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters